Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

AI and PET scans join forces to spot lung trouble in rare muscle disease

NCT ID NCT07531446

First seen Apr 23, 2026 · Last updated Jun 23, 2026 · Updated 7 times

Summary

This study looks at 200 people with dermatomyositis, a rare muscle disease that often affects the lungs. Researchers are using special PET scans and machine learning to create a model that can better predict if a patient has interstitial lung disease. The goal is to improve diagnosis without invasive procedures.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MACHINE LEARNING are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Department of Nuclear Medicine & Institute for medical imaging technology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,

    Shanghai, Shanghai Municipality, China

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to a more accurate, non-invasive way to diagnose lung complications in dermatomyositis patients.

What could go wrong

This is an observational study using existing scans, not a treatment trial. The model may not perform well in broader populations or different hospitals.

Conditions

The condition(s) this trial relates to.

dermatomyositis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.